Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kína4. fázis

Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease

A legfontosabb adatok

Ki végzi
The First Affiliated Hospital with Nanjing Medical University
Hol
Nanjing (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
4. fázis
Résztvevők
240 fő, tervezett
Kezdés
2018. máj. 1.
Várható befejezés
2030. júl. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Methimazole
A regiszteradat frissítve
2023. december 11.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with Graves' hyperthyroidism (an overactive thyroid). It compares two ways of adjusting the dose of methimazole.

Életkor
18 to 65 years
Nem
Men and women
A betegség stádiuma
Graves' hyperthyroidism diagnosed by a doctor.
Korábbi kezelés
People who used glucocorticoids or other immunosuppressants for a long time in the 3 months before joining cannot join. People in another drug trial in the last 3 months cannot join.
Biomarker vagy leletérték
Thyroid receptor antibody (TRAb) must be positive.

A részvétel fő kizáró okai

  • Other thyroid diseases, such as subacute thyroiditis, thyroid nodules or high-function adenoma
  • History of cancer, heart failure, coronary heart disease or other autoimmune diseases
  • Poorly controlled high blood pressure (diastolic ≥100mmHg or systolic ≥160 mmHg)
  • Low white blood cells (< 3.0×109) or neutrophils (< 1.5× 109), ALT or AST more than 2 times the upper normal limit, or serum creatinine above normal
  • Pregnant or breastfeeding women, or women who may be pregnant

A regiszter feltételei, szó szerint

Mind a 31 feltétel megnézéseKevesebb

Ki vehet részt

  • Graves hyperthyroidism (responsible for doctors' clinical diagnosis)
  • Age 18-65, for both men and women
  • Thyroid receptor antibody (TRAb) was positive
  • Take part in this research voluntarily and sign the informed consent form

Ki nem vehet részt

  • Those who have used glucocorticoid or other immunosuppressants for a long time within 3 months before being selected
  • Those who have participated in any other drug trials within 3 months before being selected
  • Subjects who are participating in clinical research of other drugs
  • Those who can't cooperate, including those who can't complete the whole course of treatment, don't complete the follow-up as planned, and increase or decrease adjuvant drugs at will
  • During the trial, use other drugs that may affect the curative effect of this trial; Termination of Research Criteria:
  • Patients with a history of malignant tumors
  • Ill-controlled hypertension: diastolic blood pressure≥100mmHg, systolic blood pressure ≥160 mmHg
  • Other thyroid diseases: such as subacute thyroiditis, thyroid nodules, high-function adenoma
  • Patients with heart failure
  • Patients with coronary heart disease
  • Patients with other autoimmune diseases
  • Patients who are known to be allergic to any component of this medicine are allergic to the active ingredients or any auxiliary materials in the prescription
  • Patients with multiple drug allergies, allergic diseases, people with high sensitivity and drug addicts
  • Alcoholism, mental disorder or other observers who are not suitable for drug testing
  • Those who are allergic or intolerant to this drug
  • Other diseases appear during the treatment, and the treatment of accompanying diseases will interfere with the clinical observers of this medicine
  • Blood routine: the total number of white blood cells < 3.0×109 or neutrophils < 1.5× 109
  • Alanine aminotransferase(ALT) or aspartate amino transferase(AST) is greater than 2 times of the normal upper limit; When ALT or AST is less than 2 times of the normal upper limit, and the test of hepatitis B two half-and-half positive
  • Renal insufficiency: serum creatinine is higher than the upper limit of normal value
  • Pregnant women of childbearing age in the experiment
  • Pregnant and lactating women cannot rule out the possibility of pregnancy
  • Taking any medicine with unknown ingredients or using traditional Chinese medicine, the researcher judges the medicine that may affect the curative effect of hyperthyroidism
  • According to the researcher's judgment, other medical history that reduces the possibility of joining the group or complicates the joining of the group, such as frequent changes in the working environment, may easily lead to lost follow-up; Rejection Criteria:
  • The compliance of this clinical trial protocol is < 80% or > 120%
  • Those who did not meet the inclusion criteria or the exclusion criteria were found during the experiment
  • Adverse reactions or serious adverse events that patients can't tolerate occur
  • The researcher thinks it is inappropriate to continue the experiment

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 65 év között vagy?

Helyszínek itt: Kína

  • The First Affiliated Hospital of Nanjing Medical UniversityNanjing, KínaContact: Xuqin ZhengRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

In this study, the dose of methimazole was adjusted according to the different states of thyroid function, and the effects of conventional therapy and intensive therapy on the cumulative recurrence of Graves' hyperthyroidism after two years of drug withdrawal were evaluated. At the same time, the changes of immune indexes and inflammatory factors in the regulation process were evaluated. This study is a phase IV clinical study designed and carried out by the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), which is a randomized, open and routine treatment group with parallel control.

A vizsgálat 2 csoportja

  • Conventional treatment groupMár használt kezelés, összehasonlításként

    According to the thyroid function, if the initial free thyroxine(FT4) ≥ 3 times the normal value, the initial dose of methimazole is 30mg/ day, the thyroid function will be tested every four weeks, and the dose will be reduced when thyroid stimulating hormone(TSH) \> normal lower limit or free triiodothyronine(FT3) \< normal lower limit or FT4 \< normal lower limit. The dose will be reduced according to the clinical routine, specifically, every day (30 mg→20 mg→10 mg→5mg→2.5 mg) If the initial FT4 is less than 3 times the normal value, the initial dose of methimazole is 15mg/ day, and the thyroid function is tested every four weeks. When TSH is greater than the normal lower limit or FT3 is less than the normal lower limit or FT4 is less than the normal lower limit, the dose will be reduced according to the clinical routine, specifically every day for 24 months. If TSH \> 100 mIU/L occurs during the treatment, the reduction speed will be accelerated, and 1-2 dose levels can be skipped.

    Kezelés: Methimazole

  • Intensive treatment groupMár használt kezelés, összehasonlításként

    If the initial FT4≥ 3 times of normal value, the initial dose of methimazole was 30mg/ day, and the thyroid function and antibodies were detected every four weeks. When TSH≥4.2 mIU/L, the amount of methimazole began to decrease, specifically in a daily manner (30 mg→20 mg→15mg). The dose was maintained after the decrease to 15 mg. In the case of hypothyroidism, levothyroxine was added until the three antibodies (TPOAb, TGAb and TRAb) were negative. The dose was maintained for six months, and then the doses of methimazole and levothyroxine were gradually reduced until drug discontinuation (each month). If the initial FT4 was less than 3 times of normal level, the initial dose of methimazole was 15 mg/ day, and levothyroxine was added when hypothyroidism occurred. After all three antibodies were negative, the doses were gradually reduced to the point of drug discontinuation.

    Kezelés: Methimazole

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Clinical Study on the Effect of Routine Treatment and Intensive Treatment on the Regulation of Graves' Disease and the Cumulative Recurrence Two Years After Drug Withdrawal
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT05461820: ki vehet részt
A regiszteradat frissítve
2023. december 11.